Integra LifeSciences Holdings Corporation Aktie News

PHILADELPHIA, PA / ACCESS Newswire / June 9, 2025 / Kaskela Law LLC announces that it is investigating potential breach of fiduciary duty claims concerning Integra LifeSciences Holdings Corp. (NASDAQ:IART) ("Integra") on behalf of the company's long-term investors. Click here to receive additional information about your legal rights and options: https://kaskelalaw.com/cases/integra-lifesciences...

Integra LifeSciences Holdings Corporation (NASDAQ:IART ) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants Chris Ward - Senior Director, Investor Relations Mojdeh Poul - President and Chief Executive Officer Lea Knight - Executive Vice President and Chief Financial Officer Conference Call Participants Young Li - Jefferies Iseult McMahon - BTIG Vik Chopra - Wells Fargo...

PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2025.

PRINCETON, N.J., April 18, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release first quarter 2025 financial results on Monday, May 5, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET.

PHILADELPHIA, March 22, 2025 (GLOBE NEWSWIRE) -- Grabar Law Office is investigating whether the Board of Directors of Integra LifeSciences Holdings Corp. (NASDAQ: IART) breached their fiduciary duties owed to the Company.

PRINCETON, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Mojdeh Poul, chief executive officer and Lea Knight, chief financial officer will present at the 35th Annual Oppenheimer Healthcare MedTech & Services Conference on March 17, 2025 at 10:00am ET.

Integra LifeSciences had a rough 2024 as the company's quality control remediation efforts had a bigger than expected negative impact on results. Q4 '24 offered some stability with organic revenue growth and improved adjusted gross margins. 2025 guidance looks cautious, and a big cut to Q1 '25 expectations suggests that management may be pulling forward some of the lingering remediation costs.

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Integra LifeSciences Holdings Corp. (NASDAQ: IART) on behalf of long-term stockholders following a class action complaint that was filed against Integra on September 12, 2023 with a Class Period from March 11, 2019 to May 22, 202...